21.08.2008TIME: 17:07:39
LAST
8,65 €
OPEN
8,67 €
CHANGE
+0,23%
foto
HOME COMPANY PIPELINE NEWS INVESTOR RELATIONS   Search
Strategic Focus
Management Team
Board of Directors
Partners
 
 
 
 
 
The ThromboGenics Board is composed of experienced people from different disciplines and with a broad view on the Life Sciences industry. The executive members are Désiré Collen, Chairman and founder of ThromboGenics and Chris Buyse, CFO. The nonexecutive members are Landon T. Clay, Manager Member of East Hill Advisors, LLCC and partner of East Hill University Spinout Funds; Jean-Luc Dehaene, former prime minister of Belgium and vice-chairman of the European Convention; Luc Philips, Chairman of KBC Insurances and director of Kredietbank NV; Staf van Reet, Chairman of Movetis.

Dr D. Collen, MD, PhD      I  Chairman and founder of ThromboGenics

Désiré Collen holds a MD degree and PhD degree in Chemistry from the University of Leuven, Belgium. Founder of ThromboGenics, he is currently Director of the Center for Molecular and Vascular Biology of the KULeuven, and the Center for Transgene Technology and Gene Therapy of the Flanders Interuniversity Institute for Biotechnology in Leuven, Belgium. He has received four honorary doctorates and several scientific awards including the Francqui Prize (Belgium). His team discovered and initially developed tPA, currently the most effective drug for thrombolytic therapy of acute myocardial infarction. Prof. Collen is a Non-Executive Director of Beta Cell NV.      I  top

Chris Buyse      I  Chief Financial Officer

Chris Buyse brings to ThromboGenics 20 years experience in international company finance and in running and establishing best financial practice. He was previously CFO of the Belgian biotechnology company CropDesign where he coordinated its acquisition by BASF in early 2007. Before this, Mr. Buyse was Finance Director of WorldCom/MCI Belux, a European subsidiary of one of the world’s largest telecom companies, and was CFO and interim CEO of Keyware Technologies, reporting to the President of the Board. In addition, he held several financial positions as financial controller and internal auditor at Spector Photo Group, Suez Lyonnaise des Eaux and Unilever.      I  top

Landon T. Clay      I  Non-Executive Director

Mr. Clay is a Managing Member of East Hill Advisors, LLC, the general partner of East Hill University Spinouts Funds. Prior to co-founding East Hill, he was chairman and chief executive officer (CEO) of Eaton Vance Corporation, an investment management firm listed on the NYSE. He is chairman of the Clay Mathematics Institute, which he founded in 1998, ADE Corporation and the Caribbean Conservation Corporation and is a director of Golden Queen Mining Co. Ltd. He has served on the board of the Museum of Fine Arts, Boston, Middlesex School, Concord, MA, and the Smithsonian Institution, Washington, DC. Mr Clay received an AB, cum laude, from Harvard College and served as an Overseer of Harvard from 1975 to 1981. He has donated Professorships in Mathematics and in Scientific Archaeology at Harvard and financed Harvard’s share in the construction of the Magellan Telescope in Chile. He has also given smaller observational telescopes to Dexter School and Middlesex School.      I  top

Jean-Luc Dehaene      I  Non-Executive Director

Mr. Jean-Luc Dehaene has occupied several ministerial posts. He was Prime Minister of Belgium from 1992 until 1999 and vice-chairman of the European Convention. He is a member of the board of directors of Umicore NV, Inbev NV, Telindus Group NV, Domo NV and Lotus Bakeries NV. He is chairman of the board of directors of College of Europe (Bruges). He is member of the European Parliament and mayor of Vilvoorde. Mr. Dehaene studied law and political and social sciences in Namur and Leuven, Belgium.      I  top

Luc Philips      I  Non-Executive Director

Mr. Philips has a degree in commercial and financial sciences from the Hoger Instituut voor Bestuurs- en Handelswetenschappen (HIBH) in Brussels. In 1997, he was appointed to the board of directors and the executive committee of Kredietbank. From 1998 to 2003, he was managing director of the KBC Bank and Insurance Holding Company and KBC Bank. He was appointed managing director of Almanij in 2003. In the same year, he was also appointed director of the KBC Bank and Insurance Holding Company, KBC Bank, KBC Insurance and KBL, and became chairman of the audit committee of the first three of these companies. After the merger of KBC Bank and Insurance Holding Company and Almanij, Luc Philips remained chairman of the audit committee of KBC Group NV and KBC Bank, joined the audit committee of KBC Insurance, and became chairman of the board of directors of KBC Insurance and deputy chairman of the board of directors of KBC Bank. Furthermore, he serves on various boards of directors of companies that are part of KBC Group NV, of which two are active in Central Europe (K&H Bank in Hungary and Kredyt Bank in Poland). Luc Philips is also a member of the board of directors of Norkom Technologies (Ireland) en of Gemma Frisius Fonds (Belgium).      I  top
Staf Van Reet, Ir. Ph.D      I  Non-Executive Director

Dr Van Reet is chairman of FlandersBio VZW and managing director of Viziphar Biosciences BVBA, a start-up bio-pharma research and development company, and its subsidiary Viziphar Biosciences PVT Ltd (Bangalore, India) of which he is also chairman of the board of directors. He serves on various other boards including Janssen Pharmaceutica NV, the Flanders Interuniversity Institute for Biotechnology (VIB), the Antwerp Incubation Center NV (AIC), 4AZA Bioscience NV and Vivactis NV. Dr Van Reet joined Janssen Pharmaceutica, an affiliate of Johnson & Johnson, in 1972 as a scientist in the Department of Theoretical Medicinal Chemistry. In 1973 he moved to the Department of Patents and Pharmacochemical Data Processing, which he headed from 1977 to 1989. Since 1987 he took increasingly important general management responsibilities as managing director of Janssen Biotech, chairman of the management board of the Janssen Research Foundation and from 1991 to 1999 as president of the Janssen Research Foundation and managing director of Janssen Pharmaceutica NV. From 2000 until 2004 Dr Van Reet was vice president of Johnson & Johnson Development Corporation, the venturing arm of Johnson & Johnson, and from April until June 2005 he was a member of the management committee of Galapagos NV. Dr Van Reet holds a degree of engineering in Applied Biological Sciences and a Ph.D. in Agricultural Sciences from the University of Leuven, Belgium and studied law at the University of Antwerp. He is a qualified Belgian and European Patent Authority.      I  top
  All rights reserved © Thrombogenic 2006 Last update: April 14, 2008 Inspired by Echo
 
PIPELINE COMPANY HOME